Alaunos Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alaunos Therapeutics, Inc. (TCRT) on December 17, 2025. The filing discloses the entry into a Material Definitive Agreement resolving a dispute with The University of Texas M.D. Anderson Cancer Center regarding unpaid invoices under a 2019 Research and Development Agreement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or liquidity metrics. The only specific financial figure disclosed is the settlement obligation:
- Total Settlement Amount: $285,055
- Payment Structure: Installment payments over six months.
- Initial Payment: $142,528 due on or before December 30, 2025.
- Subsequent Payments: Five installments of $28,506 each, due monthly from January 30, 2026, through May 30, 2026.
Material Changes
The primary material change is the resolution of the dispute with MD Anderson. The Company has agreed to pay the full outstanding amount in installments, replacing the previous status of unpaid invoices. The agreement includes mutual general releases of claims related to the unpaid invoices, with exceptions for breach of the settlement and certain ongoing matters (Protocol 2006-0676).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations. The primary risk disclosed is the immediate cash outflow required to satisfy the settlement terms. The filing notes that the description of the agreement is qualified by reference to the full text filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can meet the $142,528 payment due by December 30, 2025.
- Review the full text of the Settlement Agreement (Exhibit 10.1) to understand the scope of the mutual releases and the specific ongoing matters excluded from the release.
- Confirm whether the 2019 Research and Development Agreement remains active or if the settlement terminates the relationship with MD Anderson.
- Assess the impact of the $285,055 liability on the Company's balance sheet and working capital.